Exercise to enhance tumour outcomes in advanced oesophageal cancer V1

• Research type

  Research Study

• Full title

  Optimizing prehabilitation exercise to enhance tumour outcomes in advanced oesophageal cancer

• IRAS ID

  326527

• Contact name

  Adam Frampton

• Contact email

  adam.frampton@surrey.ac.uk

• Sponsor organisation

  University of SUrrey

• Clinicaltrials.gov Identifier

  SPON 2023 22 FHMS, SPON 2023 22 FHMS

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  Regular exercise can significantly improve physical and mental health before, during and after cancer treatment, improve treatment tolerance, and reduce the time needed in the hospital. In patients receiving therapy for breast and prostate cancer, exercise training is associated with changes in circulating blood levels of immune cells that are important in the elimination of tumours. However, in humans, whether these circulating immune cells reach the tumour remains unknown. In animal studies, exercise training produces more immune cells in the tumour. These immune cell infiltrates contribute to the destruction and reduction of the size of the tumour and are a vital component of effective immunotherapy.
  In our recent pilot study that assessed muscle fitness and quality of life changes in patients receiving neoadjuvant chemotherapy before oesophageal cancer surgery, we have preliminary data that suggests exercise promotes immune cell infiltrates into tumours. Our exercise program resulted in significantly more tumour infiltrating immune cells that potentially suggest exercise could facilitate an immunotherapy treatment option rather than surgery. Critically, we observed associations between larger changes in aerobic fitness and more immune cell infiltrates, suggesting a dose-response relationship between exercise and immune infiltration. Therefore, we aim to compare our previous exercise program with a targeted exercise program designed to increase aerobic fitness and, as such, increase the number of infiltrating immune cells

• REC name

  West Midlands - Black Country Research Ethics Committee

• REC reference

  23/WM/0205

• Date of REC Opinion

  19 Dec 2023

• REC opinion

  Further Information Favourable Opinion